Visium Funds Fall as Pharmaceutical, Energy Weigh on Portfolios

  • Endo, Allergan push Visium Balanced to third month of losses
  • Endo `is purely collateral damage' from Valeant, letter says

Visium Asset Management’s biggest funds extended losses in March as positions in pharmaceutical companies Endo International Plc and Allergan Plc sank.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.